Ulipristal marketed as, a progesterone receptor antagonist (PRA). It acts by depriving uterine fibroids of growth stimulation due to progesterone.
The treatment consists of one tablet of 5 mg to be taken orally once daily for up to 3 months, and it should be started during the first week of a menstrual cycle. There are no data available on treatment with a duration longer than 3 months or on repeat courses of treatment. Therefore, treatment duration should not exceed 3 months.
The benefits with Esmya are its ability to reduce fibroid-related bleeding, anaemia and fibroid size. Ulispristal showed better efficacy compared to placebo (a dummy) at reducing bleeding and anaemia, but only moderated efficacy with regards to fibroid volume reduction.
The most common side effects are amenorrhea, endometrial thickening and hot flush.
The treatment consists of one tablet of 5 mg to be taken orally once daily for up to 3 months, and it should be started during the first week of a menstrual cycle. There are no data available on treatment with a duration longer than 3 months or on repeat courses of treatment. Therefore, treatment duration should not exceed 3 months.
The benefits with Esmya are its ability to reduce fibroid-related bleeding, anaemia and fibroid size. Ulispristal showed better efficacy compared to placebo (a dummy) at reducing bleeding and anaemia, but only moderated efficacy with regards to fibroid volume reduction.
The most common side effects are amenorrhea, endometrial thickening and hot flush.
No comments:
Post a Comment